KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Short-Term Debt issuances (2016 - 2025)

Eli Lilly (LLY) has disclosed Short-Term Debt issuances for 16 consecutive years, with -$400000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-Term Debt issuances fell 100.01% year-over-year to -$400000.0, compared with a TTM value of -$4.3 billion through Dec 2025, down 134.23%, and an annual FY2025 reading of -$4.3 billion, down 134.23% over the prior year.
  • Short-Term Debt issuances was -$400000.0 for Q4 2025 at Eli Lilly, up from -$4.1 billion in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $4.6 billion in Q4 2023 and bottomed at -$5.2 billion in Q1 2024.
  • Average Short-Term Debt issuances over 5 years is -$11.8 million, with a median of -$2.5 million recorded in 2021.
  • The sharpest move saw Short-Term Debt issuances plummeted 9632.0% in 2022, then soared 1988.2% in 2023.
  • Year by year, Short-Term Debt issuances stood at -$2.5 million in 2021, then tumbled by 9632.0% to -$243.3 million in 2022, then skyrocketed by 1988.2% to $4.6 billion in 2023, then plummeted by 33.78% to $3.0 billion in 2024, then tumbled by 100.01% to -$400000.0 in 2025.
  • Business Quant data shows Short-Term Debt issuances for LLY at -$400000.0 in Q4 2025, -$4.1 billion in Q3 2025, and $1.6 billion in Q2 2025.